KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Amortization (2017 - 2020)

Historic Amortization for Takeda Pharmaceutical (TAK) over the last 4 years, with Q1 2020 value amounting to $15.4 billion.

  • Takeda Pharmaceutical's Amortization rose 140813.64% to $15.4 billion in Q1 2020 from the same period last year, while for Mar 2020 it was $13.8 billion, marking a year-over-year change of. This contributed to the annual value of $43.5 billion for FY2020, which is 8462675.92% up from last year.
  • Takeda Pharmaceutical's Amortization amounted to $15.4 billion in Q1 2020, which was up 140813.64% from -$1.2 billion recorded in Q1 2019.
  • Over the past 5 years, Takeda Pharmaceutical's Amortization peaked at $15.4 billion during Q1 2020, and registered a low of -$1.2 billion during Q1 2019.
  • For the 4-year period, Takeda Pharmaceutical's Amortization averaged around $3.4 billion, with its median value being -$243.9 million (2017).
  • Its Amortization has fluctuated over the past 5 years, first crashed by 40084.71% in 2018, then surged by 140813.64% in 2020.
  • Over the past 4 years, Takeda Pharmaceutical's Amortization (Quarter) stood at $242.9 million in 2017, then tumbled by 400.85% to -$730.8 million in 2018, then plummeted by 61.43% to -$1.2 billion in 2019, then skyrocketed by 1408.14% to $15.4 billion in 2020.
  • Its last three reported values are $15.4 billion in Q1 2020, -$1.2 billion for Q1 2019, and -$730.8 million during Q4 2018.